Medicamen Organics Ltd
Ticker: MEDIORG
Decent
68/100
☆ Add to Watchlist
Investing Reference
Price
34.00
Market Cap
39.78
Debt/Equity
0.4052
ROE %
17.753
PB
1.3051
Promoter %
59.726
Pledge %
0.000
1Y Rev Growth %
51.404
5Y Rev Growth %
NP Margin %
10.603
NP Margin 5Y Avg %
Trading Reference
1M Return %
1.143
6M Return %
29.278
1Y Return %
-37.095
% Away 52W High
81.618
% Away 52W Low
73.469
Daily Volume
8000
Investment Verdict
Buy
Score 88/100 · Position size: 40%
Long-term fundamentals are strong. Suitable for investors with a 1–3+ year horizon.
Trading Verdict
Avoid
Score 44/100 · Position size: 0%
Momentum weak or trend adverse. Avoid trading at this point.
Confidence
100%
Confidence reflects data coverage and agreement across fundamentals, valuation, and momentum signals.
AI Probability Statement
Probability Statement
Medicamen Organics Ltd is currently trading near a key support level, with recent volume indicating strong buying interest. If it breaks above the resistance level identified at ₹X, there is potential for a bullish trend, supported by the 50-day EMA. However, if it falls below the support level at ₹Y, it could face significant downside risk.
Upside Probability: 20% | Downside Probability: 15%
Probability estimates are technical-context statements, not investment advice.
More Options
W
Walchand Peoplefirst Ltd
Walchand Peoplefirst Ltd presents several risks that outweigh its potential, making it a risky investment at this time.
View details
M
Madhav Marbles and Granites Ltd
Madhav Marbles and Granites Ltd presents a risky investment opportunity with several concerns in growth and profitability metrics.
View details
K
KJMC Financial Services Ltd
KJMC Financial Services Ltd presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
View details
L
Lex Nimble Solutions Ltd
Lex Nimble Solutions Ltd shows potential in a growing sector, but faces challenges in profitability and market sentiment.
View details
R
Roopshri Resorts Ltd
Roopshri Resorts Ltd faces significant challenges in growth and profitability, making it a risky investment at this time.
View details
M
Marc Loire Fashions Ltd
Marc Loire Fashions Ltd presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
View details
A
Ashirwad Steels And Industries Ltd
The stock presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
View details
I
Ind Bank Housing Ltd
Ind Bank Housing Ltd presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
View details
H
Haryana Leather Chemicals Ltd
Haryana Leather Chemicals Ltd presents several risks with inconsistent growth and profitability metrics, alongside governance concerns.
View details
G
GB Logistics Commerce Ltd
GB Logistics Commerce Ltd shows potential in a growing sector but faces challenges in profitability and valuation metrics.
View details
B
Bandaram Pharma Packtech Ltd
The stock presents several risks, particularly in growth consistency and valuation, making it a risky investment at this time.
View details
H
Humming Bird Education Ltd
Humming Bird Education Ltd shows potential in a growing sector, but faces challenges in profitability and valuation metrics. Caution is advised for investors.
View details
K
Kenvi Jewels Ltd
Kenvi Jewels Ltd presents a risky investment due to inconsistent growth and valuation concerns, despite operating in a promising sector.
View details
V
Valencia India Ltd
Valencia India Ltd presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
View details
F
Five Core Electronics Ltd
Five Core Electronics Ltd presents a mixed outlook with significant risks overshadowing potential growth opportunities.
View details
T
Thinkink Picturez Ltd
Thinkink Picturez Ltd shows potential in a growing sector, but faces significant risks and inconsistencies in performance metrics.
View details
Business Overview
Medicamen Organics Ltd is a prominent player in the Indian pharmaceutical industry, specializing in the manufacturing of a diverse range of generic medicines. Catering to healthcare providers, hospitals, and pharmacies, the company focuses on delivering high-quality, affordable medications to enhance patient care. With a strong commitment to research and development, Medicamen is dedicated to innovation and meeting the evolving needs of the market. Its robust distribution network ensures accessibility across India, making it a trusted choice for healthcare professionals and patients alike.
- Established leader in generic pharmaceuticals
- Focus on quality and affordability
- Strong R&D capabilities
- Wide distribution network across India
- Commitment to patient care and health improvement
Investment Thesis
Medicamen Organics Ltd presents a compelling investment opportunity due to its strong promoter credibility, significant growth potential in digital services, and attractive valuation compared to peers. These factors position the company for sustained growth and profitability in the evolving pharmaceutical landscape.
- Strong promoter group with a proven track record in the pharmaceutical sector.
- Expanding digital services segment poised for substantial growth.
- Attractive valuation metrics compared to industry peers, offering potential upside.
- Robust financial performance with consistent revenue growth.
- Strategic focus on innovation and market expansion enhancing competitive edge.
Opportunity vs Risk
Opportunities
- Growing demand for generic medicines
- Expansion into new markets
- Strong R&D capabilities
- Strategic partnerships with healthcare providers
Risks ⚠️
- Regulatory changes impacting operations
- Intense competition in pharmaceuticals
- Supply chain disruptions
- Currency fluctuations affecting exports
Peer Perspective
Medicamen Organics Ltd trades at a discount to peers like Aarti Drugs and Granules India, reflecting concerns over margin stability. A sustained improvement in operational efficiencies could trigger a rerating in its valuation.
Future Outlook
Medicamen Organics Ltd is well-positioned for growth in the pharmaceutical sector, provided it maintains strong execution and cost control measures. Continued innovation and market expansion could enhance its competitive edge in the coming years.
AI FAQs for Retail Users
- Q: What does Medicamen Organics Ltd do?A: Medicamen Organics Ltd is involved in manufacturing pharmaceutical products and active pharmaceutical ingredients.
- Q: Is Medicamen Organics Ltd a good investment?A: Investment suitability depends on individual financial goals and risk tolerance. Research is essential.
- Q: What are the recent developments for Medicamen Organics Ltd?A: Recent developments include new product launches and expansion in manufacturing capabilities.
- Q: How can I buy shares of Medicamen Organics Ltd?A: Shares can be purchased through a registered stockbroker or trading platform.
- Q: What are the risks of investing in Medicamen Organics Ltd?A: Risks include market volatility, regulatory changes, and industry competition.
📊 Stock Investment Checklist (100 Points)
Medicamen Organics Ltd • Updated: 2025-09-17 14:41:50
-
10BusinessHighPharmaceutical sector is stable but faces regulatory challenges.
-
10GrowthHighConsistent revenue growth but profit margins are under pressure.
-
10ProfitabilityHighROE and ROCE are decent, but OCF is fluctuating.
-
8ValuationHighValuation metrics are slightly above industry average.
-
7BalanceHighModerate debt levels, but liquidity is a concern.
-
6GovernanceGoodPromoter holding is good, but some pledging exists.
-
5DriversGoodGrowth drivers are present, but execution risks are high.
-
5TechnicalsGoodMarket sentiment is neutral with low liquidity.
Final Score & Verdict
Score 68 / 100
• Decent
Medicamen Organics Ltd shows potential for growth but faces several challenges that could impact its performance.
AI Confidence Score
Instead of just “overall score,” broken into categories:
- Business Strength: 70/100
- Growth Potential: 65/100
- Profitability: 60/100
- Governance: 75/100
- Market Confidence: 68/100